Payment overview · 2025
General Payments
$1,818.09
86 reported records · 17 companies
Healthcare provider profile · identity verified
Douglas R Dreffer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DERRY, NH · NPI 1316940802
Verified facts
What the public records show
CMS Open Payments records show Douglas R Dreffer, M.D. received $1,818.09 in general payments during 2025 across 86 reported records.
ABBVIE INC. accounted for 31.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $571.47 | 31.4% | 24 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $241.78 | 13.3% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $173.68 | 9.6% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $165.34 | 9.1% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.92 | 6.9% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $86.96 | 4.8% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $83.36 | 4.6% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $78.59 | 4.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.97 | 3.0% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $46.59 | 2.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.42 | 1.9% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $33.03 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.88 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.28 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.65 | 1.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $23.82 | 1.3% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $15.35 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,818.09 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $389.72 | 16 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $229.85 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $139.03 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $131.03 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $131.03 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $113.32 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.01 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.19 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $86.96 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $78.59 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $75.49 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $62.97 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $52.04 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $52.02 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $52.02 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $52.02 | 6 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $48.64 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.19 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $46.59 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.02 | 3 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.88 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.09 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 89 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 339 | 110 |
| Lisinopril | Lisinopril | 210 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 164 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 157 | 55 |
| Oxycodone Hcl | Oxycodone Hcl | 125 | 20 |
| Losartan Potassium | Losartan Potassium | 115 | 39 |
| Omeprazole | Omeprazole | 113 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 45 |
| Gabapentin | Gabapentin | 93 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 41 |
| Eliquis | Apixaban | 89 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 16 |
| Prednisone | Prednisone | 86 | 47 |
| Sertraline Hcl | Sertraline Hcl | 81 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 27 |
| Clonazepam | Clonazepam | 74 | 17 |
| Metformin Hcl | Metformin Hcl | 68 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 17 |
| Lorazepam | Lorazepam | 64 | 24 |
| Simvastatin | Simvastatin | 63 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 23 |
| Alprazolam | Alprazolam | 59 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 20 |
| Furosemide | Furosemide | 54 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | 23 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 51 | suppressed |
| Carvedilol | Carvedilol | 46 | 14 |
| Trazodone Hcl | Trazodone Hcl | 44 | 21 |
| Spironolactone | Spironolactone | 40 | 11 |
| Allopurinol | Allopurinol | 38 | 12 |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Bupropion Xl | Bupropion Hcl | 36 | 13 |
| Tramadol Hcl | Tramadol Hcl | 36 | 18 |
| Potassium Chloride | Potassium Chloride | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 16 |
| Meloxicam | Meloxicam | 32 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | 11 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | 11 |
| Estradiol | Estradiol | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 22 |
| Finasteride | Finasteride | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Clotrimazole | Clotrimazole | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Nexium | Esomeprazole Magnesium | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 11 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,818.09 · 86 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, BEXSERO, Belbuca, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, GARDASIL 9, INGREZZA, JARDIANCE, Jornay PM, Kerendia, MOUNJARO, NUPLAZID, NURTEC ODT, Ozempic, PAXLOVID, PENMENVY, PREVNAR 20, QULIPTA, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XTAMPZA, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error